

# Supplementary figures

The contribution of germline pathogenic variants in breast cancer genes to contralateral breast cancer in *BRCA1/BRCA2/PALB2*-negative women

A. Larionov, E. Fewings, J. Redman, M. Goldgraben, G. Clark, J. Boice, P. Concannon, J. Bernstein, D.V. Conti, the WECARE Study Collaborative Group, M. Tischkowitz

<b><i>Supp. Figure S1: Study flowchart</i></b> .....	<b>2</b>
<b><i>Supp. Figure S2: PCA for Group 1</i></b> .....	<b>3</b>
A: Projecting to 1KGP .....	3
B: Scree plot .....	3
<b><i>Supp. Figure S3: PCA for Group 2</i></b> .....	<b>4</b>
A: Projecting to 1KGP .....	4
B: Scree plot .....	4
<b><i>Supp. Figure S4: WECARE-Group1 + NFFE PCA Scree plot</i></b> .....	<b>5</b>
<b><i>Supp. Figure S5: Burden of PGVs stratified by latency</i></b> .....	<b>6</b>
A: Group 1 .....	6
B: Group 2 .....	6
<b><i>Supp. Figure S6: WECARE-Group1 + NFFE PGVs burden</i></b> .....	<b>7</b>

Supp. Figure S1: Study flowchart

#### Secondary bioinformatics

following Broad's Best Practices

- FastQC and FASTQ Trimming
- Alignment (BWA MEM, GRCh37)
- BAM files QC and processing
- Variant Calling (GATK HC)
- Joined genotyping with NFFE
- Variants QC and filtering (VQSR & hard filters)
- Variants normalization & splitting multiallelic sites
- Variants Annotation (VEP, ClinVar, CADD)

#### Samples check and filtering


- pairwise concordance
- concordance with previous GWAS data

#### PCA

- PC-s for regression models,
- ethnicity assessment by projecting to 1KGP


#### Statistical analysis

- crude counts for bar-plots
- regression models for statistical significance




Supp. Figure S2: PCA for Group  
1

**Projecting Group 1 to 1KGP  
using 13,487 variants**




B: Scree plot



Supp. Figure S3: PCA for Group


2

**Projecting Group 2 to 1KGP  
using only 161 variants**




B: Scree plot

**Scree Plot**




Supp. Figure S4: WECARE-Group1 + NFFE PCA Scree plot




## Supp. Figure S5: Burden of PGVs stratified by latency

### A: Group 1




### B: Group 2



Note: In CBC the latency is the time between the 1<sup>st</sup> cancer and 2<sup>nd</sup> cancer (lack of 2<sup>nd</sup> cancer in UBC)

## Supp. Figure S6: WECARE-Group1 + NFFE PGVs burden



Note: The NFFE<UBC<CBC trend is statistically significant (POLR test  $p = 0.02$ ). The absolute AF values are smaller than in WECARE-only analysis because variants with low coverage in NFFE samples were removed (see Figure 1 and Methods section in the main text).